AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims:

1. (Canceled)

2. (Currently amended) A compound of the Formula II:



II

wherein:

X is C_{1-10} alkylene ~~or C_{2-10} alkenylene~~;

R_{A1} and R_{B1} are taken together to form a fused aryl ring, wherein the aryl ring is unsubstituted or ~~substituted by one or more R groups, or~~ substituted by one R_3 group~~, or substituted by one R_3 group and one R group~~;

~~R is selected from the group consisting of:~~

~~halogen,~~

~~hydroxy,~~

~~alkyl,~~

~~alkenyl,~~

~~haloalkyl,~~

~~alkoxy,~~

~~alkylthio, and~~

~~$N(R_9)_2$;~~

R_3 is selected from the group consisting of:

-Z-R_4,

-Z-X'-R_4, and

-Z-X'-Y-R_4, and

-Z-X'-R_5;

Y' is selected from the group consisting of:

a bond,

-C(O)-,

-C(S)-,

-$S(O)_2$-,

-$S(O)_2$-N(R_8)-,



,

-C(O)-O-,

-C(O)-N(R_8)-,

-C(S)-N(R_8)-,

-C(O)-N(R_8)-$S(O)_2$-,

-C(O)-N(R_8)-C(O)-, and

-C(S)-N(R_8)-C(O)-,



,

-C(O)-C(O)-,

-C(O)-C(O)-O-, and

-C(=NH)-N(R_8)-;

R_1 is selected from the group consisting of:

-R_4,

-X'-R_4, and

-X'-Y-R_4,

-X'-Y-X'-Y-R_4, and

~~-X'-R_5~~;

R_2 and R_{2a} are independently selected from the group consisting of:

hydrogen,

alkyl,

~~alkenyl,~~

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, ~~alkenyl,~~ aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

~~hydroxy,~~

alkyl,

haloalkyl,

~~hydroxyalkyl,~~

alkoxy,

~~dialkylamino,~~

~~-$S(O)_{0-2}$-alkyl,~~

~~-$S(O)_{0-2}$-aryl,~~

~~-NH-$S(O)_2$-alkyl,~~

~~-NH-$S(O)_2$-aryl,~~

~~haloalkoxy,~~

halogen, and

~~cyano,~~

~~nitro,~~

aryl~~,~~

~~heteroaryl,~~

~~heterocyclyl,~~

~~aryloxy,~~

~~arylalkyleneoxy,~~

~~-C(O)-O-alkyl,~~

~~-C(O)-N(R$_8$)$_2$,~~

~~-N(R$_8$)-C(O)-alkyl,~~

~~-O-(CO)-alkyl, and~~

~~-C(O)-alkyl~~;

~~or R$_2$ and R$_{2a}$ together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:~~



and ;

X' is selected from the group consisting of alkylene~~, alkenylene, alkynylene,~~ and arylene~~, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups~~;

Y is selected from the group consisting of:

~~-S(O)$_{0-2}$-,~~

~~-S(O)$_2$-N(R$_8$)-,~~

-C(R$_6$)-,

~~-C(R$_6$)-O-,~~

~~-O-C(R$_6$)-,~~

~~-O-C(O)-O-,~~

-N(R$_8$)-Q-,

-C(R$_6$)-N(R$_8$)-,

~~-O-C(R$_6$)-N(R$_8$)-,~~

~~-C(R$_6$)-N(OR$_9$)-,~~


,


,


,


, and


;

Z is a bond ~~or O~~;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

~~R_5 is selected from the group consisting of:~~


;

R_6 is ~~selected from the group consisting of~~ =O ~~and =S~~;

R_7 is C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, and C_{1-10} alkyl~~, C_{2-10} alkenyl, C_{1-10} alkoxy C_{1-10} alkylenyl, and aryl C_{1-10} alkylenyl~~;

~~R_9 is selected from the group consisting of hydrogen and alkyl;~~

R_{10} is C_{3-8} alkylene;

~~A is selected from the group consisting of CH_2, O, C(O), $S(O)_{0-2}$, and $N(R_4)$;~~

Q is selected from the group consisting of a bond, $-C(R_6)-$, ~~$C(R_6)C(R_6)$,~~ $-S(O)_2-$, and $-C(R_6)-N(R_8)-W-$~~, $S(O)_2N(R_8)$, $C(R_6)O$, and $C(R_6)N(OR_9)$~~;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$; and

W is selected from the group consisting of a bond, -C(O)-, and $-S(O)_2-$; ~~and~~

~~a and b are independently integers from 1 to 6 with the proviso that a+b is ≤ 7;~~ or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Currently amended) The compound of claim 2 of the Formula IIIa:



IIIa

wherein:

X is C_{1-10} alkylene ~~or C_{2-10} alkenylene~~;

Y' is selected from the group consisting of:

a bond,

-C(O)-,

~~-C(S)-,~~

-$S(O)_2$-,

-$S(O)_2$-$N(R_8)$-,



,

-C(O)-O-,

-$C(O)$-$N(R_8)$-,

-$C(S)$-$N(R_8)$-,

~~-C(O)-N(R8)-S(O)2-,~~

-$C(O)$-$N(R_8)$-$C(O)$-, and

~~-C(S)-N(R8)-C(O)-,~~



[[,]]

~~-C(O)-C(O)-,~~

~~-C(O)-C(O)-O-, and~~

~~-C(=NH)-N(R8)-~~;

~~R is selected from the group consisting of:~~

~~halogen,~~

~~hydroxy,~~

~~alkyl,~~

~~alkenyl,~~

~~haloalkyl,~~

~~alkoxy,~~

~~alkylthio, and~~

~~-N(R9)2;~~

R_1 is selected from the group consisting of:

-R_4,

-X'-R_4, and

-X'-Y-R_4,

~~-X'-Y-X'-Y-R_4, and~~

~~-X'-R_5~~;

R_2 and R_{2a} are independently selected from the group consisting of:

hydrogen,

alkyl,

~~alkenyl,~~

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, ~~alkenyl,~~ aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

~~hydroxy,~~

alkyl,

haloalkyl,

~~hydroxyalkyl,~~

alkoxy,

~~dialkylamino,~~

~~-S(O)$_{0-2}$-alkyl,~~

~~-S(O)$_{0-2}$-aryl,~~

~~-NH-S(O)$_2$-alkyl,~~

~~-NH-S(O)$_2$-aryl,~~

~~haloalkoxy~~,

halogen, and

~~cyano,~~

~~nitro,~~

aryl~~,~~

~~heteroaryl,~~

~~heterocyclyl,~~

~~aryloxy,~~

~~arylalkyleneoxy,~~

~~-C(O)-O-alkyl,~~

~~-C(O)-N(R_8)$_2$,~~

~~-N(R_8)-C(O)-alkyl-,~~

~~-O-(CO)-alkyl, and~~

~~-C(O)-alkyl~~;

~~or R_2 and R_{2a} together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:~~



;

R_3 is selected from the group consisting of:

-Z-R_4,

-Z-X'-R_4, and

-Z-X'-Y-R_4~~, and~~

~~-Z-X'-R_5~~;

n is ~~an integer from~~ 0 ~~to 4~~;

m is 0 or 1;

~~with the proviso that when m is 1, then n is 0 or 1;~~

X' is selected from the group consisting of alkylene~~, alkenylene, alkynylene,~~ and arylene~~, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups~~;

Y is selected from the group consisting of:

~~-S(O)$_{0-2}$-,~~

~~-S(O)$_2$-N(R_8)-,~~

-C(R_6)-, and

~~-C(R_6)-O-,~~

~~-O-C(R_6)-,~~

~~-O-C(O)-O-,~~

-N(R_8)-Q-[[,]]

~~-C(R_6)-N(R_8)-,~~

~~-O-C(R_6)-N(R_8)-,~~



~~, and~~



;

Z is a bond ~~or -O-~~;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

~~R_5 is selected from the group consisting of:~~



, , , and ;

R_6 is ~~selected from the group consisting of~~ =O ~~and =S~~;

R_7 is C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, and C_{1-10} alkyl~~, C_{2-10} alkenyl, C_{1-10} alkoxy C_{1-10} alkylenyl, and aryl C_{1-10} alkylenyl~~;

~~R_9 is selected from the group consisting of hydrogen and alkyl;~~

R_{10} is C_{3-8} alkylene;

~~A is selected from the group consisting of CH_2, O, C(O), $S(O)_{0-2}$, and $N(R_4)$;~~

Q is selected from the group consisting of a bond, $-C(R_6)-$, ~~$C(R_6)C(R_6)$,~~ $-S(O)_2-$, and $-C(R_6)-N(R_8)-W-$~~, $S(O)_2N(R_8)$, $C(R_6)O$, and $C(R_6)N(OR_9)$~~;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$; and

W is selected from the group consisting of a bond, -C(O)-, and $-S(O)_2-$; ~~and~~

~~a and b are independently integers from 1 to 6 with the proviso that a+b is ≤ 7~~;

or a pharmaceutically acceptable salt thereof.

5. (Currently amended) The compound of claim 2 of the Formula IIIaa:



IIIaa

wherein:

X is C_{1-10} alkylene ~~or C_{2-10} alkenylene~~;

Y' is selected from the group consisting of:

a bond,

-C(O)-,

~~C(S),~~

$-S(O)_2-$,

$-S(O)_2-N(R_8)-$,



,

-C(O)-O-,

-C(O)-N(R_8)-,

-C(S)-N(R_8)-,

~~-C(O)-N(R_8)-S(O)$_2$-,~~

-C(O)-N(R_8)-C(O)-, and

~~-C(S)-N(R_8)-C(O)-,~~



[[,]]

~~-C(O)-C(O)-,~~

~~-C(O)-C(O)-O-, and~~

~~-C(=NH)-N(R_8)-~~;

R_2 and R_{2a} are independently selected from the group consisting of:

hydrogen,

alkyl,

~~alkenyl,~~

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,

heterocyclylalkylenyl, and

alkyl, ~~alkenyl,~~ aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

~~hydroxy,~~

alkyl,

haloalkyl,

~~hydroxyalkyl,~~

alkoxy,

~~dialkylamino,~~

~~$-S(O)_{0-2}$-alkyl,~~

~~$-S(O)_{0-2}$-aryl,~~

~~$-NH-S(O)_2$-alkyl,~~

~~$-NH-S(O)_2$-aryl,~~

~~haloalkoxy,~~

halogen, and

~~cyano,~~

~~nitro,~~

aryl~~,~~

~~heteroaryl,~~

~~heterocyclyl,~~

~~aryloxy,~~

~~arylalkyleneoxy,~~

~~-C(O)-O-alkyl,~~

~~$-C(O)-N(R_8)_2$,~~

~~$-N(R_8)-C(O)$-alkyl,~~

~~-O-(CO)-alkyl, and~~

~~-C(O)-alkyl~~;

R_1 is selected from the group consisting of:

$-R_4$,

$-X'-R_4$, and

$-X'-Y-R_4$~~,~~

~~$-X'-Y-X'-Y-R_4$, and~~

~~$-X'-R_5$~~;

X' is selected from the group consisting of alkylene~~, alkenylene, alkynylene,~~ and arylene~~, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be~~

~~optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups~~;

Y is selected from the group consisting of:

~~-S(O)$_{0-2}$-,~~

~~-S(O)$_2$-N(R_8)-,~~

-C(R_6)-,

~~-C(R_6)-O-,~~

~~-O-C(R_6)-,~~

~~-O-C(O)-O-,~~

-N(R_8)-Q-, and

-C(R_6)-N(R_8)-[[,]]

~~-O-C(R_6)-N(R_8)-,~~



~~, and~~



;

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

~~R_5 is selected from the group consisting of:~~



R_6 is =O;

R_8 is selected from the group consisting of hydrogen, and C_{1-10} alkyl~~, C_{2-10} alkenyl, C_{1-10} alkoxy C_{1-10} alkylenyl, and aryl C_{1-10} alkylenyl~~;

~~R_9 is selected from the group consisting of hydrogen and alkyl;~~

R_{10} is C_{3-8} alkylene;

~~A is selected from the group consisting of $-CH_2-$, $-O-$, $-C(O)-$, $-S(O)_{0-2}-$, and $-N(R_4)-$;~~

Q is selected from the group consisting of a bond, $-C(R_6)-$, ~~$-C(R_6)-C(R_6)-$~~, $-S(O)_2-$, and $-C(R_6)-N(R_8)-W-$~~, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, and $-C(R_6)-N(OR_9)-$~~;

V is selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$; and

W is selected from the group consisting of a bond, -C(O)-, and $-S(O)_2-$;

or a pharmaceutically acceptable salt thereof.

6.-13. (Canceled)

14. (Previously presented) The compound or salt of claim 4 wherein m and n are 0.

15.-18. (Canceled)

19. (Currently amended) The compound or salt of claim 2 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, and $-X'-Y-R_4$~~, and $-X'-R_5$~~; wherein X' is alkylene; Y is $-N(R_8)-C(O)-$, $-N(R_8)-S(O)_2-$, $-N(R_8)-S(O)_2-N(R_8)-$, $-N(R_8)-C(O)-N(R_8)-$, or $-N(R_8)-C(O)-N(R_8)-C(O)-$,



, or ; and R_4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen~~; and R_5 is~~



, , or .

20. (Currently amended) The compound or salt of claim 19 wherein R_1 is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or -X'-Y-R_4; X' is ethylene, propylene, or butylene; Y is -NH-C(O)-, -NH-$S(O)_2$-, -NH-$S(O)_2$-$N(R_8)$-, -NH-C(O)-$N(R_8)$-, or -NH-C(O)-NH-C(O)-~~;, or~~



; and R_8 is hydrogen or methyl.

21. (Previously presented) The compound or salt of claim 2 wherein X is C_{1-4} alkylene.

22. (Previously presented) The compound or salt of claim 21 wherein X is methylene.

23. (Previously presented) The compound or salt of claim 2 wherein Y' is selected from the group consisting of a bond, -C(O)-, -C(O)-O-, -$S(O)_2$-, -$S(O)_2$-$N(R_8)$-, -C(O)-$N(R_8)$-, -C(S)-$N(R_8)$-, -C(O)-$N(R_8)$-C(O)-, and



.

24. (Previously presented) The compound or salt of claim 23 wherein Y' is selected from the group consisting of -C(O)-, -$S(O)_2$-, and -C(O)-$N(R_8)$-.

25. (Currently amended) The compound or salt of claim 2 wherein R_2 and R_{2a} are independently selected from the group consisting of: hydrogen, alkyl, ~~alkenyl,~~ aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, ~~alkenyl,~~ aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -$S(O)_{0-2}$-alkyl, -$S(O)_{0-2}$-aryl, -NH-$S(O)_2$-alkyl, -NH-$S(O)_2$-aryl, haloalkoxy, halogen, cyano, nitro, aryl, heteroaryl, heterocyclyl, aryloxy, arylalkyleneoxy, -C(O)-O-alkyl, -C(O)-$N(R_8)_2$, -$N(R_8)$-C(O)-alkyl, -O-(CO)-alkyl, and -C(O)-alkyl.

26. (Previously presented) The compound or salt of claim 2 wherein R_{2a} is hydrogen.

27. (Currently amended) The compound or salt of claim 2 wherein R_2 and R_{2a} are independently selected from the group consisting of hydrogen, alkyl, ~~alkenyl,~~ aryl, heteroaryl, wherein the alkyl, ~~alkenyl,~~ aryl, and heteroaryl are each optionally substituted with one or more substitutents selected from the group consisting of C_{1-10} alkyl, aryl, heteroaryl, C_{1-10} alkoxy, -O-C(O)-C_{1-10} alkyl, -C(O)-O-C_{1-10} alkyl, halogen, and cyano.

28. (Previously presented) The compound or salt of claim 2 wherein R_2 is alkyl or substituted alkyl, and R_{2a} is hydrogen.

29. (Previously presented) The compound or salt of claim 28 wherein R_2 is methyl or cyclopropyl, and R_{2a} is hydrogen.

30-34. (Canceled)

35. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

36. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

37. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

38. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

39. (Currently amended) The compound or salt of claim 4 or 5 wherein R_1 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, and -X'-Y-R_4~~, and -X'-R_5~~; wherein X' is alkylene; Y is -N(R_8)-C(O)-, -N(R_8)-$S(O)_2$-, -N(R_8)-$S(O)_2$-N(R_8)-, -N(R_8)-C(O)-N(R_8)-, or -N(R_8)-C(O)-N(R_8)-C(O)-[[,]];



, or ; and R_4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen~~; and R_5 is~~



, , or .

40. (Currently amended) The compound or salt of claim 39 wherein R_1 is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or -X'-Y-R_4; X' is ethylene, propylene, or butylene; Y is -NH-C(O)-, -NH-$S(O)_2$-, -NH-$S(O)_2$-N(R_8)-, -NH-C(O)-N(R_8)-, or -NH-C(O)-NH-C(O)-~~;, or~~



; and R_8 is hydrogen or methyl.

41. (Previously presented) The compound or salt of claim 4 or 5 wherein X is C_{1-4} alkylene.

42. (Previously presented) The compound or salt of claim 41 wherein X is methylene.

43. (Previously presented) The compound or salt of claim 4 or 5 wherein Y' is selected from the group consisting of a bond, -C(O)-, -C(O)-O-, -$S(O)_2$-, -$S(O)_2$-$N(R_8)$-, -C(O)-$N(R_8)$-, -C(S)-$N(R_8)$-, -C(O)-$N(R_8)$-C(O)-, and 

.

44. (Previously presented) The compound or salt of claim 43 wherein Y' is selected from the group consisting of -C(O)-, -$S(O)_2$-, and -C(O)-$N(R_8)$-.

45. (Previously presented) The compound or salt of claim 4 or 5 wherein R_2 and R_{2a} are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -$S(O)_{0-2}$-alkyl, -$S(O)_{0-2}$-aryl, -NH-$S(O)_2$-alkyl, -NH-$S(O)_2$-aryl, haloalkoxy, halogen, cyano, nitro, aryl, heteroaryl, heterocyclyl, aryloxy, arylalkyleneoxy, -C(O)-O-alkyl, -C(O)-$N(R_8)_2$, -$N(R_8)$-C(O)-alkyl, -O-(CO)-alkyl, and -C(O)-alkyl.

46. (Previously presented) The compound or salt of claim 4 or 5 wherein R_{2a} is hydrogen.

47. (Previously presented) The compound or salt of claim 4 or 5 wherein R_2 and R_{2a} are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, wherein the alkyl, alkenyl, aryl, and heteroaryl are each optionally substituted with one or more substituents selected from the group consisting of C_{1-10} alkyl, aryl, heteroaryl, C_{1-10} alkoxy, -O-C(O)-

C_{1-10} alkyl, -C(O)-O-C_{1-10} alkyl, halogen, and cyano.

48. (Previously presented) The compound or salt of claim 4 or 5 wherein R_2 is alkyl or substituted alkyl, and R_{2a} is hydrogen.

49. (Previously presented) The compound or salt of claim 48 wherein R_2 is methyl or cyclopropyl, and R_{2a} is hydrogen.

50.-64. (Canceled)

65. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 4 or 5 in combination with a pharmaceutically acceptable carrier.

66. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 4 or 5 to the animal.

67.-72. (Canceled)